Postoperative @entity1753 for XXXX improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center.

@entity1 @entity260 @entity1753 @entity1442 @entity356
BACKGROUND: The benefits of @entity1753 in the context of a D2 lymph node dissection are controversial. The aim was to investigate the effects of postoperative @entity1753 on the survival of @entity1 with a curative resection for @entity356 and a D2 lymph node dissection. METHODS: We performed a retrospective cohort study. @entity1 operated from 1996 to 2013 were selected. We compared long term survival of @entity1 treated with surgery alone and those with surgery plus postoperative @entity1753 . A multivariate analysis for survival was applied in every stage. RESULTS: The study included 580 @entity1 . Two-hundred and four @entity1 received postoperative @entity1753 ( @entity1753 ) and 376 @entity1 were treated only with surgery (SU). @entity1 in the @entity1753 group were younger (60 versus 68, p  <  0.001), had a lower rate of multiple organ resection (21% versus 39%, p  <  0.001) and had @entity260 (14% versus 32%, p  <  0.001). In the @entity1753 group, @entity1 had more @entity1442 (stage III; 77% versus 66%, p  <  0.001). No difference was found in lymph nodes resected (31 versus 30, p  =  ns). The median survival with @entity1753 was 33 months (39% 5 year survival) and 22 months (31% 5 year survival) for @entity1 without @entity1753 (p  =  0.003). On multivariate analysis, @entity1 with stage IIIB and IIIC had significantly better overall and disease specific long-term survival with @entity1753 . CONCLUSIONS: These results suggest that there is a long-term survival benefit for @entity1 treated with postoperative @entity1753 for stages IIIB and IIIC @entity356 after D2 lymph node dissection.
